OFEV Slows Progression of Fibrosis, Lung Imaging in Phase 3b Trial Shows

OFEV Slows Progression of Fibrosis, Lung Imaging in Phase 3b Trial Shows

Pulmonary fibrosis treatment OFEV (nintedanib) slows the progression of lung scarring, according to high-resolution scans used in a Phase 3b clinical trial.

Computed tomography imaging demonstrated for the first time that six months of Ofev could reduce  the progression of patients’ lung fibrosis lesions, compared with a placebo. Two previous Phase 3 trials have also shown the therapy’s effectiveness.

Researchers presented the Phase 3b trial results at the Pulmonary Fibrosis Foundation Summit 2017 in Nashville, Nov. 9-11. It was titled “Effect of nintedanib on disease progression: results from a Phase IIIb trial in patients with idiopathic pulmonary fibrosis (IPF).

“With the aid of high-resolution CT scans, we have observed a reduction in the progression of lung fibrosis with Ofev versus placebo,” Dr. Lisa Lancaster, clinical director of the Interstitial Lung Disease Program at Vanderbilt University Medical Center, said in a press release.

“These encouraging results demonstrate that through an imaging scan we identified differential responses in fibrotic changes between groups that will help doctors make informed treatment decisions,” added Lancaster, the lead investigator of the study.

Developed by Boehringer Ingelheim, Ofev is one of the first drugs that the U.S. Food and Drug Administration and European Union have approved as a treatment for idiopathic pulmonary fibrosis, or IPF.

Ofev inhibits an enzyme involved in the promotion of fibrosis signaling pathways. Those pathways trigger the accumulation of fibroblasts — lung cells that promote scarring — and the production of collagen, a protein associated with fibrosis.

The Phase 2 TOMORROW (NCT00514683) trial and the Phase 3 INPULSIS studies (NCT01335464 and NCT01335477) showed that 150 mg of Ofev twice a day for more than 52 weeks could improve IPF patients’ lung function, compared with a placebo.

Results of the long-term INPULSIS-ON extension trial (NCT01619085) also have demonstrated Ofev’s potential to slow lung function decline in IPF.

The Phase 3b trial (NCT01979952) investigators used high-resolution CT scans to evaluate Ofev’s ability to slow fibrosis. The study included 113 patients with IPF who received either 150 mg of Ofev or a placebo twice a day.

After six months, the average CT lung fibrosis score for the Ofev-treated patients was 11.4 percent, versus 14.6 percent for the placebo-treated patients. A lower score indicates less fibrosis progression.

Ofev-treated patients also experienced less lung function decline than the placebo patients, researchers said. The team used a lung function measure known as forced vital capacity — the amount of air that a person can forced exhale after taking the deepest breath possible.

“This study reaffirms the beneficial effect of Ofev for reducing lung function decline and slowing disease progression, and is the first to suggest that there may be a differential effect of Ofev treatment versus placebo in lung fibrosis change,” said Dr. Thomas Leonard, executive director of Clinical Development and Medical Affairs, Specialty Care, at Boehringer Ingelheim.

“We look forward to presenting additional findings from this study at major medical congresses next year and confirmation of these results in future studies,” Leonard added.

Average Rating
0 out of 5 stars. 0 votes.
My Rating:


  1. Walter Luberda says:

    So is it wise to go off of Esbriet and try ofvo.
    I have been on Esbriet for 20 months and the rash’s on mine skin get worse every fall

    • I was on esbriet for six months and could not go outside , my skin reminded me of alligator skin. I have changed to Ofev and have had no adverse reaction to the sun. I have been on Ofev for 12 months now

  2. Nitza Kuilan says:

    How is your opinion for stem cells treatment for IPF????
    wHERE is the best in USA?
    My husband use Ofev 150 mg about 18 months twice daily and IPF is in control.
    Thank you, Blessings!

  3. Diane McCullough says:

    My husband passed away September 2015 with pulmonary fibrosis. He didn’t have the benefit of this medicine. Someone said on FB the other day that they could not afford it. Call your company and ask about help to pay.. Some companies do offer scholarships. Believe me if it will help you any at all it is worth it. I would have sold everything I own if it would have saved my husband. God bless you all. For the spouses of those who have this horrible disease I pray for you as well. If you need someone to talk to I’m here. Hold on to your family,church family and friends . I could not have made it with out mine.There is always hope and God is still in the miracle business.

    • Rebby says:

      How very kind of you to offer. My husband has IPF and is on Esbriet and his Pulmonologist is impressed with how his CT looks. It has definitely slowed it down. You are so right, there is always hope and God is still performing miracles. He will decide.

    • Jennifer Kripp says:

      My husband passed away June 2017 from pneumonia a result of this disease. He was 86 years old and was never offered any alternative medication. I am like you would have paid any amount of money to ease his suffering,

  4. Rosalie Smith says:

    My husband has been on it for almost 2 years. He is off of oxygen and lungs have no additional scaring. Open Door is picking up the cost over what our insurance pays. Open Door pays the majority of it. Our Pulmonologist recommend it and help us get set up with the Open Door. The only side effect is almost chronic diarrhea, which is a known side effect.

    Good Luck

  5. Bill says:

    I have been on Ofev for 11 months. I have had two CT scans since then (last one 2 weeks ago) and both my lung function results and the scan itself shows virtually no change. In fact, there was a slight improvement in lung function results actually, but not enough to be statistically significant.

    My mother and two brothers didn’t have the benefit of these treatments and all passed away from this condition (IPF).

    • Sharon Diane McCullough says:

      Dear Bill, I thank God that this medicine was able to slow down or stop your fibrosis. It didn’t come in time for my husband. I hope you continue to improve. This is a horrible sickness and I pray every day for a complete cure.

Leave a Comment

Your email address will not be published. Required fields are marked *